2020
Cytomorphologic features of thyroid disease in patients with DICER1 mutations: A report of cytology–histopathology correlation in 7 patients
Darbinyan A, Morotti R, Cai G, Prasad ML, Christison‐Lagay E, Dinauer C, Adeniran AJ. Cytomorphologic features of thyroid disease in patients with DICER1 mutations: A report of cytology–histopathology correlation in 7 patients. Cancer Cytopathology 2020, 128: 746-756. PMID: 32897650, DOI: 10.1002/cncy.22329.Peer-Reviewed Original ResearchConceptsDICER1 mutationsThyroid diseaseThyroid carcinomaScreening of patientsFine-needle aspiration samplesMonitoring of patientsDiagnostic cytologic featuresPapillary thyroid carcinomaGermline DICER1 mutationsThyroid fine-needle aspiration samplesFNA evaluationUndetermined significanceDifferent somatic variantsThyroid cancerScant colloidNeoplastic lesionsHistopathological analysisCytomorphologic featuresDICER1 syndromeModerate cellularityCytologic featuresFollicular carcinomaFollicular lesionsInconspicuous nucleoliFollicular neoplasm
2017
Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2016
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016, 122: 1097-1107. PMID: 26784937, DOI: 10.1002/cncr.29887.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCarcinomaCarcinoma, PapillaryChildDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansMaleMutationNew EnglandNuclear Pore Complex ProteinsOncogene Proteins, FusionProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-etsProto-Oncogene Proteins c-retReceptor, trkAReceptor, trkCRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionThyroid Cancer, PapillaryThyroid Neoplasms
2004
The MACIS Score Predicts the Clinical Course of Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Francis GL. The MACIS Score Predicts the Clinical Course of Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2004, 17: 339-344. PMID: 15112910, DOI: 10.1515/jpem.2004.17.3.339.Peer-Reviewed Original Research
2003
Treatment of Recurrent Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Francis GL. Treatment of Recurrent Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2003, 16: 1033-1040. PMID: 14513881, DOI: 10.1515/jpem.2003.16.7.1033.Peer-Reviewed Original ResearchConceptsRecurrent papillary thyroid carcinomaPapillary thyroid carcinomaThyroid carcinomaYears of ageThird remissionCervical nodesPersistent diseaseClinical coursePoor prognosisSecond recurrenceHigh mortalityRemissionChildrenCarcinomaRecurrenceMortalityTreatmentAdultsPrevious dataPatientsPrognosisDiseaseTumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL. Tumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2003, 16: 693-702. PMID: 12880118, DOI: 10.1515/jpem.2003.16.5.693.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaExtent of diseaseLarger tumor sizeTumor sizeExtensive diseaseInitial treatmentThyroid carcinomaRadioactive iodine treatmentClass IV patientsInitial therapyFirst remissionIV patientsPersistent diseaseMultifocal diseasePatientsClass IIIRemissionClass IIIodine treatmentDiseaseClass IDiagnosisTreatmentCarcinomaChildren
2002
Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents
Patel A, Fenton C, Terrell R, Powers P, Dinauer C, Tuttle R, Francis G. Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents. Journal Of Endocrinological Investigation 2002, 25: 675-683. PMID: 12240898, DOI: 10.1007/bf03345100.Peer-Reviewed Original ResearchConceptsInducible nitric oxide synthaseEndothelial nitric oxide synthaseFollicular thyroid carcinomaPapillary thyroid carcinomaNitric oxide synthaseAutoimmune lesionsBenign adenomasMultinodular goiterNitric oxideThyroid tumorsNormal thyroidOxide synthaseThyroid carcinomaAutoimmune thyroid diseaseNeuronal NO synthaseVascular endothelial growth factorHigh-power fieldMatrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents
Patel A, Straight A, Mann H, Duffy E, Fenton C, Dinauer C, Tuttle R, Francis G. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. Journal Of Endocrinological Investigation 2002, 25: 403-408. PMID: 12035934, DOI: 10.1007/bf03344028.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaFollicular thyroid carcinomaThyroid carcinomaTIMP-1MMP-1MMP-1 expressionMatrix metalloproteinasesMT1-MMPRecurrent papillary thyroid carcinomaTumor-associated inflammatory cellsPrevious pathological studiesTumor-associated lymphocytesDifferentiated thyroid carcinomaTIMP-1 expressionMatrix metalloproteinase expressionThyroid cancer cellsIntensity of stainingBenign thyroid lesionsMembrane type-1 matrix metalloproteinasesInflammatory cellsPathological studiesNormal thyroid cellsMalignant lesionsBenign lesionsMetalloproteinase expressionThyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents
Straight A, Patel A, Fenton C, Dinauer C, Tuttle R, Francis G. Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents. Journal Of Endocrinological Investigation 2002, 25: 302-308. PMID: 12030599, DOI: 10.1007/bf03344009.Peer-Reviewed Original ResearchConceptsFollicular thyroid carcinomaPapillary thyroid carcinomaThyroid carcinomaMalignant tumorsTelomerase expressionDisease-free survivalAggressive clinical courseChildhood thyroid cancerHigh recurrence riskYr of ageBenign thyroid lesionsLow telomerase expressionAutoimmune lesionsClinical courseDistant metastasisDirect invasionThyroid cancerBenign tumorsBlind examinerOriginal tumorBenign lesionsRecurrence riskTumorsThyroid lesionsCarcinoma
2001
Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults1
Gupta S, Patel A, Folstad A, Fenton C, Dinauer C, Tuttle R, Conran R, Francis G. Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults1. The Journal Of Clinical Endocrinology & Metabolism 2001, 86: 1346-1354. PMID: 11238531, DOI: 10.1210/jcem.86.3.7310.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdolescentAdultCarcinoma, MedullaryCarcinoma, PapillaryCell DivisionChildDisease-Free SurvivalFemaleHumansImmunohistochemistryKi-67 AntigenLeukocyte Common AntigensLymphatic MetastasisLymphocytesMaleNeoplasm MetastasisNeoplasm Recurrence, LocalThyroid NeoplasmsConceptsDisease-free survivalPapillary thyroid carcinomaImproved disease-free survivalTumor-associated lymphocytesNumber of lymphocytesThyroid cancerThyroid carcinomaFollicular thyroid carcinomaHigh-power fieldYoung adultsAutoimmune thyroiditisImmune responseKi-67 positive lymphocytesRegional lymph node involvementMultifocal papillary thyroid carcinomaChildhood papillary thyroid carcinomasLymph node involvementDifferentiated thyroid cancerDifferentiated thyroid carcinomaLong-term outcomesPower fieldPresence of lymphocytesMedullary thyroid carcinomaHigh proliferation indexMajority of PTC
2000
Over‐expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma
Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle R, Francis G. Over‐expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clinical Endocrinology 2000, 53: 635-644. PMID: 11106926, DOI: 10.1046/j.1365-2265.2000.01124.x.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaFollicular thyroid carcinomaDisease-free survivalHGF/SF expressionMedullary thyroid carcinomaThyroid carcinomaHepatocyte growth factor/scatter factorGrowth factor/scatter factorYoung adultsFree survivalHigh riskHGF/SF receptorHGF/SFShorter disease-free survivalNormal thyroidExtent of diseaseSF expressionBenign thyroid disordersExpression of cMetIntensity of expressionMalignant thyroid lesionsClinical outcomesRetrospective groupThyroid disordersThyroid cancerThe Expression of Vascular Endothelial Growth Factor and the Type 1 Vascular Endothelial Growth Factor Receptor Correlate with the Size of Papillary Thyroid Carcinoma in Children and Young Adults
Fenton C, Patel A, Dinauer C, Robie D, Tuttle R, Francis G. The Expression of Vascular Endothelial Growth Factor and the Type 1 Vascular Endothelial Growth Factor Receptor Correlate with the Size of Papillary Thyroid Carcinoma in Children and Young Adults. Thyroid 2000, 10: 349-357. PMID: 10807064, DOI: 10.1089/thy.2000.10.349.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdolescentAdultCarcinoma, PapillaryCase-Control StudiesChildEndothelial Growth FactorsFemaleHumansLymphokinesMaleProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesReceptors, Growth FactorThyroid NeoplasmsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsConceptsVascular endothelial growth factorExpression of VEGFPapillary thyroid carcinomaEndothelial growth factorThyroid carcinomaBenign lesionsYoung adultsClinical outcomesThyroid cancerPTC sizeVEGF expressionFlt-1Growth factorRetrospective clinical outcomesChildhood thyroid cancerThyroid tissue blocksFollicular thyroid carcinomaFlt-1 expressionRecurrent diseaseSolid tumorsCarcinomaVEGF receptorsReceptor correlatesLesionsTissue blocksTyrosine kinase expression is increased in papillary thyroid carcinoma of children and young adults.
Patel A, Fenton C, Ramirez R, Dinauer CA, Tuttle RM, Nikiforov YE, Gary FL. Tyrosine kinase expression is increased in papillary thyroid carcinoma of children and young adults. Frontiers In Bioscience-Landmark 2000, 5: a1-9. PMID: 10702379, DOI: 10.2741/patel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCarcinoma, PapillaryChildEndothelial Growth FactorsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphokinesMalePhosphorylationProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-metReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorRegistriesThyroid NeoplasmsTyrosineVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsConceptsThyroid carcinomaRecurrence riskYoung adultsTK expressionTyrosine kinaseThyroid tissue blocksPapillary thyroid carcinomaTyrosine kinase expressionHepatocyte growth factor/scatter factorGrowth factor/scatter factorYounger patientsClinical behaviorBenign lesionsThyroid glandMalignant transformationIndividual tumorsTissue blocksKinase expressionCarcinomaDifferent tyrosine kinasesAdultsScatter factorChildrenPTCRisk
1999
Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma
Dinauer C, Tuttle R, Robie D, McClellan D, Francis G. Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. Journal Of Pediatric Surgery 1999, 34: 1799-1804. PMID: 10626858, DOI: 10.1016/s0022-3468(99)90316-0.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerRisk of complicationsExtensive surgeryRadioactive iodineHigh riskThyroid hormonesRecurrent papillary thyroid cancerIncidence of complicationsRecurrence-free survivalRisk of recurrenceYears of agePapillary thyroid carcinomaInitial surgeryPermanent hypoparathyroidismSubtotal thyroidectomyTotal thyroidectomyAdjunctive therapySurgical complicationsSurgical groupYounger patientsMultifocal diseaseMultifocal tumorsContralateral lobeOptimal treatmentThyroid cancer